Myovant Shares Jump Premarket on FDA Expanded OK of Myfembree
By Colin Kellaher
Shares of Myovant Sciences Ltd. rose more than 15% in premarket
trading Monday after the biopharmaceutical company and partner
Pfizer Inc. won U.S. Food and Drug Administration expanded approval
of Myfembree for the management of moderate to severe pain
associated with endometriosis in premenopausal women.
The FDA had been slated to act on the application for expanded
approval in early May but extended its review after the companies
submitted more information regarding bone mineral density at the
The agency last year approved Myfembree for the management of
heavy menstrual bleeding associated with uterine fibroids in
premenopausal women. Myovant and Pfizer are jointly developing and
Myovant shares, which closed Friday at $15.12, were recently up
at $17.50 in premarket trading.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
August 08, 2022 06:38 ET (10:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
から 8 2022 まで 9 2022
から 9 2021 まで 9 2022